Close
Back to NLTX Stock Lookup
Pages: 1 2 3 4 »» Last Page

Neoleukin Therapeutics (NLTX) – Company Press Releases

Dec 14, 2023 07:00 PM Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Sep 22, 2023 08:00 AM Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Jul 18, 2023 06:30 AM Neurogene and Neoleukin Announce Definitive Merger Agreement
Mar 8, 2023 05:00 PM Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
Mar 8, 2023 05:00 PM Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
Dec 12, 2022 01:00 PM Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Dec 12, 2022 01:00 PM Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Nov 14, 2022 04:03 PM Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
Nov 14, 2022 04:03 PM Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
Nov 3, 2022 09:05 AM Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
Nov 3, 2022 09:05 AM Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
Aug 9, 2022 04:02 PM Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Aug 9, 2022 04:02 PM Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Aug 3, 2022 08:00 AM Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
Aug 3, 2022 08:00 AM Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
Jul 27, 2022 08:00 AM Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
Jul 27, 2022 08:00 AM Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
May 16, 2022 08:00 AM Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
May 16, 2022 08:00 AM Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
May 9, 2022 04:05 PM Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
May 9, 2022 04:05 PM Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
May 5, 2022 08:00 AM Neoleukin Therapeutics to Present at Upcoming Investor Conferences
May 5, 2022 08:00 AM Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Apr 13, 2022 10:00 AM Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
Apr 13, 2022 10:00 AM Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
Apr 7, 2022 08:00 AM Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
Apr 7, 2022 08:00 AM Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
Mar 15, 2022 08:00 AM Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
Mar 15, 2022 08:00 AM Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
Mar 8, 2022 04:01 PM Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
Mar 8, 2022 04:01 PM Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
Mar 1, 2022 04:03 PM Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
Mar 1, 2022 04:03 PM Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
Feb 22, 2022 08:00 AM Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
Feb 22, 2022 08:00 AM Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
Feb 3, 2022 08:00 AM Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
Feb 3, 2022 08:00 AM Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
Jan 10, 2022 08:00 AM Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
Jan 10, 2022 08:00 AM Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
Jan 10, 2022 06:00 AM Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
Jan 10, 2022 06:00 AM Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
Dec 11, 2021 05:30 PM Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
Dec 11, 2021 05:30 PM Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
Nov 12, 2021 07:05 AM Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Nov 12, 2021 07:05 AM Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Nov 9, 2021 08:00 AM Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Nov 9, 2021 08:00 AM Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2021 04:05 PM Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
Nov 4, 2021 04:05 PM Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
Oct 1, 2021 09:07 AM Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Pages: 1 2 3 4 »» Last Page

Back to NLTX Stock Lookup